所有图片(1)
About This Item
经验公式（希尔记法）:
C10H18O4
CAS号:
分子量:
202.25
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
化驗
≥95% (HPLC)
形狀
oil
顏色
colorless to slightly yellow
溶解度
DMSO: ≥10 mg/mL
儲存溫度
−20°C
SMILES 字串
CCCC(=O)OCOC(=O)C(C)(C)C
InChI
1S/C10H18O4/c1-5-6-8(11)13-7-14-9(12)10(2,3)4/h5-7H2,1-4H3
InChI 密鑰
GYKLFBYWXZYSOW-UHFFFAOYSA-N
應用
AN-9 is a HDAC inhibitor with antimetastatic and antiangiogenic properties. These anticancer activities are thought to occur by reducing vascularization and the expression of bFGF and HIF-1α.
生化／生理作用
HDAC Inhibitor tested as an anti-cancer drug; butyric acid pro-drug
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類（WGK）
nwg
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Suzanne M Cutts et al.
Oncology research, 15(4), 199-213 (2007-09-08)
The anticancer drug Adriamycin is widely used in cancer chemotherapy and is classified as a topoisomerase II inhibitor. However, in the presence of formaldehyde, Adriamycin also forms high levels of DNA adducts. In this study, a new series of butyric
S M Cutts et al.
Cancer research, 61(22), 8194-8202 (2001-11-24)
The interaction of Adriamycin and pivaloyloxymethyl butyrate (AN-9) was investigated in IMR-32 neuroblastoma and MCF-7 breast adenocarcinoma cells. Adriamycin is a widely used anticancer drug, whereas AN-9 is an anticancer agent presently undergoing Phase II clinical trials. The anticancer activity
A Aviram et al.
International journal of cancer, 56(6), 906-909 (1994-03-15)
A butyric acid pro-drug, pivaloyloxymethyl butyrate, AN-9, developed in our laboratory, was previously shown to act as a differentiation-inducing and an anti-cancer agent. In this study we have shown that both AN-9 and butyric acid caused a transient hyperacetylation of
Nataly Tarasenko et al.
Clinical & experimental metastasis, 25(7), 703-716 (2008-05-29)
Histone deacetylase inhibitory prodrugs that are metabolized to butyric acid and formaldehyde possess antineoplastic properties and low toxicity. We sought to characterize the antiangiogenic and antimetastatic activities of two lead prodrugs, pivaloyloxymethyl butyrate (AN-9) and butyroyloxymethyl-diethyl phosphate (AN-7) in murine
Erole Hobdy et al.
Current opinion in investigational drugs (London, England : 2000), 5(6), 628-634 (2004-07-10)
Titan is developing AN-9 for the potential treatment of various cancers. AN-9 is a histone deacetylase inhibitor analog of butyric acid that causes apoptosis of cancer cells through signaling cellular differentiation. In March 2001, a phase I/II study involving patients
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门